Literature DB >> 33768074

Pleural Effusion Related to Chronic Hepatitis B Virus Reactivation: A Rare Association.

Ana Oliveira1, Diana Valadares2, Felipe Nery2,3,4.   

Abstract

Despite worldwide vaccination campaigns, hepatitis B virus (HBV) infection remains a major public health problem. The natural history ranges from asymptomatic infection to severe liver injury or failure, chronic complications or reactivation episodes. The effects of HBV on the organism are immunomediated, possibly triggering extrahepatic manifestations. Since 1971, only a few cases of pleural effusion related to HBV infection have been described. We report HBV-associated pleural effusion occurring during a viral reactivation episode. Antiviral treatment directed towards pleural effusion related to HBV infection should be dictated by underlying liver disease severity and not pleural effusion severity. LEARNING POINTS: In the presence of pleural effusion of unknown origin, especially if with simultaneous acute hepatitis, a viral aetiology should be suspected and pursued.The severity of liver disease and not the pleural effusion should guide antiviral treatment. © EFIM 2021.

Entities:  

Keywords:  Hepatitis B virus; extrahepatic manifestations; pleural effusion; viral reactivation

Year:  2021        PMID: 33768074      PMCID: PMC7977048          DOI: 10.12890/2021_002270

Source DB:  PubMed          Journal:  Eur J Case Rep Intern Med        ISSN: 2284-2594


  11 in total

1.  Spontaneous HBsAg seroconversion after severe flare of chronic hepatitis B infection.

Authors:  Akif Altinbas; Ilhami Yüksel; Melih Pamukcu; Fuat Ekiz; Omer Basar; Osman Yüksel
Journal:  Ann Hepatol       Date:  2010 Apr-Jun       Impact factor: 2.400

2.  Hepatitis B surface antigen and e antigen in pleural effusion: a case report.

Authors:  E Tabor; R P Russell; R J Gerety; L F Barker; W D Hillis; D R Jackson
Journal:  Gastroenterology       Date:  1977-11       Impact factor: 22.682

3.  EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection.

Authors: 
Journal:  J Hepatol       Date:  2017-04-18       Impact factor: 25.083

4.  Incidence and determinants of spontaneous hepatitis B surface antigen seroclearance: a community-based follow-up study.

Authors:  Jessica Liu; Hwai-I Yang; Mei-Hsuan Lee; Sheng-Nan Lu; Chin-Lan Jen; Li-Yu Wang; San-Lin You; Uchenna H Iloeje; Chien-Jen Chen
Journal:  Gastroenterology       Date:  2010-04-29       Impact factor: 22.682

5.  Pleural effusion coinciding with acute exacerbations in a patient with chronic hepatitis B.

Authors:  H S Lee; P M Yang; B F Liu; C L Lee; H C Hsu; I J Su; D S Chen
Journal:  Gastroenterology       Date:  1989-06       Impact factor: 22.682

6.  Pleural effusion associated with viral hepatitis.

Authors:  P A Gross; D N Gerding
Journal:  Gastroenterology       Date:  1971-05       Impact factor: 22.682

7.  Hepatitis B and C prevalence in Portugal: disparity between the general population and high-risk groups.

Authors:  Sofia C Carvalhana; Jorge Leitão; Ana C Alves; Mafalda Bourbon; Helena Cortez-Pinto
Journal:  Eur J Gastroenterol Hepatol       Date:  2016-06       Impact factor: 2.566

8.  Loss of HBsAg antigen during treatment with entecavir or lamivudine in nucleoside-naïve HBeAg-positive patients with chronic hepatitis B.

Authors:  R G Gish; T-T Chang; C-L Lai; R de Man; A Gadano; F Poordad; J Yang; H Brett-Smith; R Tamez
Journal:  J Viral Hepat       Date:  2009-07-19       Impact factor: 3.728

Review 9.  Management of acute hepatitis B and reactivation of hepatitis B.

Authors:  Ankur Jindal; Manoj Kumar; Shiv K Sarin
Journal:  Liver Int       Date:  2013-02       Impact factor: 5.828

10.  Seroclearance rate of hepatitis B surface antigen in 2,112 patients with chronic hepatitis in Japan during long-term follow-up.

Authors:  Mariko Kobayashi; Tetsuya Hosaka; Fumitaka Suzuki; Norio Akuta; Hitomi Sezaki; Yoshiyuki Suzuki; Yusuke Kawamura; Masahiro Kobayashi; Satoshi Saitoh; Yasuji Arase; Kenji Ikeda; Yuzo Miyakawa; Hiromitsu Kumada
Journal:  J Gastroenterol       Date:  2013-06-20       Impact factor: 7.527

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.